SecBot SecBot
8-K ·Filed Nov 6, 2026

PTIX

Protagenic Therapeutics, Inc.\new
NEUTRAL
Impact 3/10
Horizonweeks Processed11d 2h ago SEC0001493152-26-050420
8-K material event: Items 1.01
Actionable Insight • Neutral

The note's repayment trigger tied to a $1,000,000 equity raise suggests the company will likely pursue a capital raise within six months. Monitor for any equity offering announcement, which would both repay the note and dilute existing shareholders.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.5400
T+0 close · Nov 6, 2026 · via day close
Latest settled
−10.37%
T+5 · $0.4840
Vs SPY
−12.97%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $0.5400entry
  2. T+1 · 8d ago −0.83%α −3.20% · $0.5355
  3. T+5 · 4d ago −10.37%α −12.97% · $0.4840
  4. T+7 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protagenic Therapeutics issued a $250,000 promissory note to Patness LLC, bearing 1.0% simple interest, due upon the earlier of an equity raise of at least $1,000,000 or 180 days. The small debt raise signals near-term cash needs for a micro-cap biotech with no disclosed revenue.

Key Financial Metrics

Deal Value
$250.0K
Deal Type
credit_facility

Key Facts

  • Principal amount of $250,000, simple interest at 1.0% per annum
  • Maturity upon earliest of: equity capital raise of at least $1,000,000 or 180 days from November 4, 2026
  • Interest forgiven if all obligations paid within 365 days
  • Issued to Patness LLC under Section 4(a)(2) exemption
  • Customary events of default including bankruptcy and payment failure

Financial Impact

$250,000 principal with 1.0% simple interest, repayable upon a $1,000,000+ equity raise or in 180 days

debtcash

Risk Factors

  • Micro-cap biotech with no disclosed revenue may face difficulty raising $1,000,000+ equity within 180 days
  • If equity raise fails, full principal plus interest becomes due at maturity, potentially straining liquidity
  • No material financial data or operational update provided in the filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-050420
Exhibit: ex10-1.htm0001493152-26-050420
Document: 0001493152-26-050420-index-headers.html0001493152-26-050420
Document: 0001493152-26-050420-index.html0001493152-26-050420
Document: 0001493152-26-050420.txt0001493152-26-050420

Track record

3 reports on PTIX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 17, 2026today 8-K Bearish 5/10 Entry $0.4500 Now $0.4500 +0.00% settles Feb 17
  2. Nov 6, 202611d ago 8-K Neutral 3/10 Viewing Entry $0.5400 Now $0.4500 −16.67% settles Feb 4
  3. Aug 20, 202612w ago 8-K Bullish 6/10 Entry $0.7400 to $0.7400 Now $0.4500 −39.19% · 0.00% +1.08% vs SPY
Showing 3 of 3

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026